Open AccessRetrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients
Author(s) -
Akihiro Yoshimura,
Tadaaki Yamada,
Yusuke Okuma,
Rui Kitadai,
Takayuki Takeda,
Takanori Kanematsu,
Hisatsugu Goto,
Hiroto Yoneda,
Taishi Harada,
Yutaka Kubota,
Takahiro Yamada,
Koji Date,
Shinsuke Shiotsu,
Kazuhiro Nagata,
Yusuke Chihara,
Junichi Uchino,
Yasuhiko Nishioka,
K. Takayama
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.08.07
Subject(s) - medicine , docetaxel , ramucirumab , oncology , lung cancer , chemotherapy , combination therapy , retrospective cohort study , combination chemotherapy , immunotherapy , refractory (planetary science) , cancer , physics , astrobiology
Current clinical trials demonstrated that combination regimens comprising chemotherapy and immunotherapy lead to better patient outcomes compared to chemotherapy alone as the first line of treatment for non-small cell lung cancer (NSCLC). In addition, the combination therapy of docetaxel (Doc) and ramucirumab (Ram) was considered one of the standard treatments for advanced or relapsed NSCLC patients. However, little is known about the therapeutic responders of this combination therapy among previously treated NSCLC patients. In the present study, we aimed to identify predictive factors for therapeutic response, including programmed death-ligand 1 (PD-L1) expression in tumors, for Doc treatment in combination with Ram.